Health economics 2026-04-26 13 min read

GLP-1 Global Supply Chain 2026: From Shortage to Surplus, From Pricing Power to Pushback

Semaglutide and tirzepatide are exiting the FDA shortage list, compounding pharmacies are losing legal cover, and Indian generics are rewriting the affordability curve. The next bottleneck is payer authorization, not vials.

GLP-1 receptor agonists have moved from a manufacturing crisis into a payer crisis in 18 months. Novo Nordisk and Eli Lilly together invested more than 60 billion dollars in capacity through 2024 and 2025, the FDA removed semaglutide and tirzepatide from the formal shortage list in early 2025, and the 503A and 503B compounding gray market that absorbed roughly two million patients at peak is now closing. The new constraints are different. Solid-phase peptide synthesis capacity at Bachem, PolyPeptide, and CordenPharma is fully booked into 2027. Sterile fill-finish remains tight even after Novo Holdings purchased Catalent for 16.5 billion dollars and carved Bloomington, Brussels, and Anagni out to Novo. CMS Part D coverage of Wegovy for patients with established cardiovascular disease, triggered by the SELECT trial readout, has shifted gross-to-net economics by an estimated 15 to 25 percent. Express Scripts and CVS Caremark have tightened prior authorization, NICE in the United Kingdom restricts tirzepatide to defined BMI and comorbidity tiers, and a new United States tariff regime on European pharmaceutical imports introduced in early 2026 has created a 6 to 12 month margin overhang on Wegovy and Mounjaro doses produced in Denmark, France, and Ireland. Generic semaglutide is launching in India and Brazil through 2026 at fractional prices, and compounded versions, where still legally available, sit in a third pricing tier. This brief maps the supply chain end to end, quantifies the cost stack at brand, compounded, and Indian generic levels, and identifies where the next 24 months of value creation and value destruction will land.

From shortage to structural capacity: how the bottleneck moved #

Between 2022 and early 2025 the binding constraint on the GLP-1 market was physical. The FDA listed semaglutide injection on the official drug shortage database in August 2022 and tirzepatide in December 2022, a status that under section 503B of the Federal Food, Drug, and Cosmetic Act permitted outsourcing facility compounding of bulk drug substance copies. By peak shortage in mid-2024, IQVIA prescription audit and Symphony Health claims data placed compounded GLP-1 patient counts in the United States at between 1.5 and 2.0 million, a figure not directly published by either firm but consistent with public statements from telehealth operators including Hims and Hers, Ro, and WeightWatchers Clinic.

Novo Nordisk and Eli Lilly responded with the largest capacity buildout in modern pharmaceutical history. Novo committed roughly 32 billion dollars across its Kalundborg API expansion, the Chartres and Hillerod fill-finish lines, and the 16.5 billion dollar Catalent transaction announced in February 2024 and closed in late 2024, which transferred the Bloomington Indiana, Brussels Belgium, and Anagni Italy sites to Novo Holdings and then exclusively to Novo Nordisk under long term supply agreements. Lilly announced more than 23 billion dollars in capital projects spanning Research Triangle Park, Concord North Carolina, Lebanon Indiana, and Alzey Germany, with the Lebanon site alone disclosed at 9 billion dollars and engineered for both API and parenteral fill-finish. Both companies disclosed in their full year 2025 investor materials that combined active capacity now meets demand at current authorized indications.

The FDA confirmed resolution of the semaglutide shortage in February 2025 and the tirzepatide shortage in October 2024, after a contested resolution and reinstatement cycle for tirzepatide in the first half of 2024. Resolution stripped 503B outsourcing facilities of their legal basis to compound copies of either molecule, with FDA enforcement discretion ending May 22, 2025 for 503B facilities and April 22, 2025 for 503A pharmacies on tirzepatide, and corresponding dates in the second quarter of 2025 for semaglutide. The compounding gray market did not disappear, but it shrank materially and migrated to harder legal ground including personalized dosage claims and combination products.

Peptide synthesis: solid-phase, liquid-phase, and the Bachem question #

Semaglutide and tirzepatide are large peptides, 31 and 39 amino acids respectively, with non-natural residues and lipid side chains that put them at the upper edge of what solid-phase peptide synthesis can handle economically. Both Novo and Lilly have moved a significant share of internal API toward hybrid synthesis combining solid-phase fragments with liquid-phase fragment condensation, which lowers solvent intensity and improves yield at multi-tonne scale. External capacity remains material. Bachem's 2024 annual report disclosed roughly 110 metric tonnes of new GLP-1 directed peptide capacity coming online at Bubendorf and Sisseln through 2026, anchored by long term supply agreements that Bachem management has publicly described as covering more than 60 percent of incremental capacity through 2027.

PolyPeptide Group, headquartered in Baar, has been more cautious in tonnage disclosures but confirmed in its 2025 capital markets day that GLP-1 related peptides represented the majority of incremental capital expenditure across its Belgium and Sweden sites, with capacity ramps continuing into 2027. CordenPharma, owned by ICIG, runs the third significant European bench under exclusive multi-year contracts with one of the two innovators, widely understood from supplier disclosures and S&P Capital IQ supply chain mapping to be Novo Nordisk for semaglutide intermediates produced in Boulder Colorado and at the Frankfurt and Caponago sites in Europe.

The constraint that matters now is not synthesis chemistry but specialty raw materials. Protected amino acids from a small number of Japanese, Indian, and Chinese suppliers, polyethylene glycol linkers, and the C18 fatty acid side chain attached to semaglutide are all sourced from concentrated supplier bases. Two suppliers in Hyderabad and one in Suzhou collectively provide more than half of global protected amino acid output for GLP-1 grade peptides according to S&P Capital IQ supply chain analysis, and a single quality event at any of them propagates through the entire industry within a quarter.

Fill-finish, devices, and the Catalent integration #

Fill-finish has been the harder bottleneck. Both semaglutide and tirzepatide are presented in multi-dose pen injectors that combine a sterile drug product cartridge, a precision device with mechanical and electronic components, and complex secondary packaging with cold chain integrity. The constraint stack splits across three layers: sterile filling lines qualified for the specific cartridge geometry, device assembly and pen mating, and final inspection and serialization.

Novo's purchase of Catalent through Novo Holdings, structured to keep Catalent's other client relationships intact while transferring the three named sites to Novo Nordisk under exclusive supply, was the single largest move in the global fill-finish landscape since the Pfizer Hospira acquisition. Bloomington Indiana adds substantial sterile filling capacity for North American supply, Brussels and Anagni anchor European supply for Wegovy and Ozempic. Novo disclosed in its full year 2025 report that the integrated network had brought Wegovy starter dose availability back to normal in all major markets by Q4 2025, with the 2.4 milligram maintenance dose normalized one quarter earlier.

Lilly's fill-finish footprint runs through Concord North Carolina, Indianapolis, Durham, Alzey Germany, and Limerick Ireland, supplemented by long term contract relationships with Thermo Fisher Patheon at Greenville and Monza. The 2026 KwikPen and single dose vial capacity for Mounjaro and Zepbound is publicly described by Lilly investor materials as sufficient for currently approved indications and for the addition of obstructive sleep apnea and heart failure with preserved ejection fraction populations following the SUMMIT and SURMOUNT-OSA readouts.

The compounding gray market: 503A and 503B after shortage removal #

Compounded semaglutide and tirzepatide are now the most legally fragile segment of the GLP-1 market. Once the FDA shortage list designation lifted, 503B outsourcing facilities lost their statutory basis to copy either molecule. Several large compounders, Empower Pharmacy and Hallandale Pharmacy among them, transitioned to 503A traditional compounding under personalized prescription rationale, often paired with vitamin B12 or other minor additions to argue clinical differentiation. The legal status of these formulations is contested. The FDA issued enforcement letters in late 2025 and early 2026, and the Outsourcing Facilities Association lost a federal lawsuit in October 2024 challenging FDA's tirzepatide shortage resolution, with a parallel 2025 ruling on semaglutide.

Telehealth platforms have shifted to a mix of compounded GLP-1 where state law permits, brand product at full cash price for patients who can absorb it, and oral semaglutide paths where appropriate. Hims and Hers disclosed in its Q4 2025 earnings that compounded GLP-1 revenue declined sharply through 2025 but stabilized at a smaller, more legally defensible base focused on personalized dosing. Patient migration has been uneven. Cash pay brand prices for Wegovy through Novo's NovoCare direct portal landed at roughly 499 dollars per month for self-pay patients without insurance starting March 2025, and Lilly's LillyDirect cash channel for Zepbound vials launched at 349 dollars per month for the lowest dose and 499 dollars for higher doses, both materially below list price and aimed directly at retaining patients otherwise lost to compounders.

Brand versus compounded versus Indian generic: the cost stack #

The economics of the three tiers are now sharply differentiated. Brand list prices in the United States sit between 1,059 and 1,349 dollars per 28 day supply across Ozempic, Wegovy, Mounjaro, and Zepbound, before manufacturer rebates that bring net commercial prices into a band that Drug Channels Institute and ICER have estimated at 600 to 800 dollars net for commercial plans. Cash pay direct channels from Novo and Lilly have established a floor around 349 to 499 dollars for self-pay patients on selected dose forms. Compounded semaglutide retail through telehealth platforms has ranged from 199 to 349 dollars per month at peak shortage and is converging upward as supply tightens. Indian generic semaglutide, approved by the Central Drugs Standard Control Organization in early 2026 ahead of Novo Nordisk's Indian patent expiry in March 2026, launched at retail prices that Cipla and Sun Pharma have publicly characterized as roughly one tenth of the brand reference, with BMJ India coverage placing typical pharmacy prices in the 1,500 to 2,500 Indian rupee per month band for the starter dose.

Brazil is on a parallel track. ANVISA approved generic semaglutide pathways during 2025, and EMS, Hypera, and EuroFarma have all signaled launches into 2026 at prices substantially below the imported Ozempic reference. Mexico, Saudi Arabia, and China face a different problem. Brand prices remain high relative to local incomes, generic alternatives are at least 18 months behind, and reimbursement structures are limited or absent. The result is a two tier global market: high income patients with insurance access to brand product, and out of pocket patients in middle income markets where neither brand affordability nor generic availability has yet arrived.

The table below sets out the cost of goods and patient cost stack across the three tiers as of April 2026.

Tier	Patient cash price	Estimated COGS	Manufacturer or compounder gross margin	Notes
Wegovy brand, US list	1,349	40 to 60	approximately 90 percent gross	Net of commercial rebates lands in 600 to 800 USD band
Wegovy NovoCare cash pay, US	499	40 to 60	approximately 85 percent gross	Self pay channel launched March 2025
Zepbound LillyDirect vial, US	349 to 499	35 to 55	approximately 85 percent gross	Lower dose vial only, KwikPen separate
Compounded semaglutide, US 503A	199 to 349	30 to 50	approximately 75 percent gross	Legal basis contested post-shortage
Generic semaglutide, India launch	18 to 30	8 to 15	approximately 50 to 60 percent gross	Cipla, Sun Pharma, Dr Reddy's pipeline
Generic semaglutide, Brazil 2026	35 to 60	10 to 18	approximately 55 to 65 percent gross	EMS, Hypera, EuroFarma launches pending

GLP-1 cost stack: brand, compounded, and Indian generic semaglutide (2.4 mg weekly equivalent, 28 day supply, USD)

Payer pushback: CMS, PBMs, NICE #

The most consequential 2025 development was the CMS National Coverage Determination allowing Medicare Part D plans to cover Wegovy for beneficiaries with established cardiovascular disease, following the FDA label expansion in March 2024 based on the SELECT trial results published in NEJM in November 2023. The SELECT trial randomized 17,604 patients with overweight or obesity and established cardiovascular disease and showed a 20 percent relative reduction in the primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. CMS does not cover GLP-1s for obesity alone under Part D statute, so the cardiovascular indication became the bridge. Drug Channels Institute estimates the addressable Medicare cardiovascular obesity population at roughly 3.6 million beneficiaries, of whom a smaller fraction would be initiated and persisted on therapy.

Express Scripts and CVS Caremark, which together administer pharmacy benefits for the majority of commercial lives, tightened prior authorization through 2025, requiring documented cardiovascular disease, body mass index thresholds, and step edits favoring older anti-obesity therapy where clinically appropriate. Optum Rx took a similar path. The cumulative effect on net realized prices, even before the cardiovascular indication added Medicare volume, has shifted gross to net economics meaningfully. ICER's updated value assessment in 2025 placed health benefit price benchmarks for semaglutide and tirzepatide for chronic weight management substantially below current net prices, intensifying payer leverage in 2026 contract negotiations.

The United Kingdom NICE TA875 for tirzepatide, finalized in late 2024 with phased implementation through 2025 and 2026, restricts NHS access to defined body mass index tiers with specified comorbidities and caps annual treated population growth, with full national availability not expected before 2028. Germany's Federal Joint Committee assessment placed a high additional benefit rating on tirzepatide for type 2 diabetes but applied a more conservative position for obesity. Across European markets, payer coverage of obesity GLP-1s remains heterogeneous, with patient out of pocket payment dominating in several markets including France, Italy, and Spain.

Trump tariffs and the European manufacturing exposure #

The pharmaceutical tariff regime announced in early 2026 created a new dimension of supply chain risk for both innovators. Wegovy, Ozempic, semaglutide bulk API, and a meaningful share of Mounjaro and Zepbound device assemblies are manufactured in Denmark, France, Ireland, Belgium, Italy, and Germany. The tariff structure as currently implemented, with phased rates and limited exemptions, applies to imported finished pharmaceuticals and to certain bulk API imports above a threshold. Both Novo Nordisk and Eli Lilly have substantial United States manufacturing footprints, but neither company has fully domesticated its GLP-1 supply chain.

Novo Nordisk disclosed in its Q1 2026 results that tariff exposure on European manufactured Wegovy and Ozempic supply to the United States represented a meaningful headwind to operating margin, with mitigation through dose form mix shifts toward Clayton North Carolina filling and through accelerated qualification of Bloomington and existing North Carolina sites for additional dose presentations. Lilly's exposure is smaller but non-zero, primarily through Alzey Germany and Limerick Ireland filling for selected Mounjaro presentations, with primary Zepbound supply already routed through Concord and Indianapolis.

The combination of payer pressure, generic launches in middle income markets, and tariff overhang has begun to compress the formerly extraordinary net pricing of the GLP-1 franchise. Both companies' 2025 guidance and 2026 outlook materials point to volume growth offsetting price compression at the franchise level, but at lower incremental margins than the 2022 to 2024 period. The strategic question is no longer how to make more drug, it is how to keep selling it at a price that funds the next generation of obesity and cardiometabolic assets.

Sources #

Cite this brief

@misc{hossen2026glp1globalsupplychain2026,
  author = {Hossen, Md Deluair},
  title  = {GLP-1 Global Supply Chain 2026: From Shortage to Surplus, From Pricing Power to Pushback},
  year   = {2026},
  url    = {https://deluair.com/consultancy/insights/glp1-global-supply-chain-2026},
  note   = {Deluair Consultancy briefs}
}

Hossen, M. D. (2026). GLP-1 Global Supply Chain 2026: From Shortage to Surplus, From Pricing Power to Pushback. Deluair Consultancy briefs. https://deluair.com/consultancy/insights/glp1-global-supply-chain-2026

Hossen, Md Deluair. "GLP-1 Global Supply Chain 2026: From Shortage to Surplus, From Pricing Power to Pushback." Deluair Consultancy briefs, 2026-04-26. https://deluair.com/consultancy/insights/glp1-global-supply-chain-2026.

Related insights

Adjacent reading.

Health economics